| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S10067-009-1149-4 |
| P698 | PubMed publication ID | 19291350 |
| P2093 | author name string | Sophia Li | |
| Primal P Kaur | |||
| Steven Berney | |||
| Virginia Chan | |||
| P2860 | cites work | Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity | Q74586915 |
| Tumor necrosis factor inhibitors for rheumatoid arthritis | Q80129386 | ||
| Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis | Q83127762 | ||
| Induction of tumour necrosis factor (TNF) receptor type p55 and p75 in patients with chronic hepatitis C virus (HCV) infection | Q27480421 | ||
| Concentrations of cytokines, soluble interleukin-2 receptor, and soluble CD30 in sera of patients with hepatitis B virus infection during acute and convalescent phases. | Q34173680 | ||
| Effect of tumour necrosis factor antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection | Q35552129 | ||
| Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. | Q35579382 | ||
| New drugs for rheumatoid arthritis | Q35777601 | ||
| Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection | Q37067835 | ||
| Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening? | Q40977680 | ||
| Inhibition of TNFalpha does not induce viral reactivation in patients with chronic hepatitis C infection: two cases | Q43030737 | ||
| Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. | Q43580784 | ||
| Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection | Q43635427 | ||
| Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease. | Q45722615 | ||
| Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. | Q55047291 | ||
| Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis | Q74002465 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatitis B | Q6853 |
| patient | Q181600 | ||
| hepatitis C | Q154869 | ||
| rheumatoid arthritis | Q187255 | ||
| adalimumab | Q348260 | ||
| TNF | Q18032037 | ||
| P304 | page(s) | 787-791 | |
| P577 | publication date | 2009-03-17 | |
| P1433 | published in | Clinical Rheumatology | Q15754927 |
| P1476 | title | Use of tumor necrosis factor-alpha (TNF-alpha) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients | |
| P478 | volume | 28 |
| Q34500921 | 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis |
| Q57245378 | 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis |
| Q56775958 | A patient with rheumatoid arthritis treated with tocilizumab together with lamivudine prophylaxis after remission of infliximab-reactivated hepatitis B |
| Q37868389 | Advances in the treatment of moderate-to-severe plaque psoriasis |
| Q38132273 | Adverse effects of golimumab in the treatment of rheumatologic diseases |
| Q37970447 | Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management |
| Q35237588 | Choice of Biologic Therapy for Patients with Rheumatoid Arthritis: The Infection Perspective |
| Q37671701 | Effect of etanercept and entecavil in a patient with rheumatoid arthritis who is a hepatitis B carrier: a review of the literature |
| Q33735206 | Hepatic flares in chronic hepatitis C: spontaneous exacerbation vs hepatotropic viruses superinfection |
| Q38155954 | Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs |
| Q45366264 | Induction of clinical remission with adalimumab-methotrexate combination therapy in a patient with rheumatoid arthritis and concomitant hepatitis C virus infection |
| Q38084250 | Kinetic profiles and management of hepatitis B virus reactivation in patients with immune-mediated inflammatory diseases |
| Q37789689 | Liver diseases associated with anti-tumor necrosis factor-alpha (TNF-α) use for inflammatory bowel disease |
| Q26771785 | Managing Patients With Psoriasis in the Busy Clinic: Practical Tips for Health Care Practitioners |
| Q42266876 | Progression of viraemia during treatment with infliximab in a patient with rheumatoid arthritis and chronic hepatitis C infection |
| Q38657207 | Reactivation of Hepatitis C Virus and Its Clinical Outcomes in Patients Treated with Systemic Chemotherapy or Immunosuppressive Therapy |
| Q37862588 | Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy |
| Q37812847 | Rheumatologic Disease and the Liver |
| Q37892162 | Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review |
| Q37766276 | Safety of anti-tumour necrosis factor-α agents in psoriasis patients who were chronic hepatitis B carriers: a retrospective report of seven patients and brief review of the literature |
| Q43035871 | Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases |
| Q39318083 | Severe candida laryngitis in a patient with rheumatoid arthritis treated with adalimumab |
| Q33810143 | Single-dose infliximab in hepatitis C genotype 1 treatment-naive patients with high serum tumour necrosis factor-alpha does not influence the efficacy of pegylated interferon alpha-2b/ribavirin therapy |
| Q37894193 | TNF alpha antagonist therapy and safety monitoring |
| Q41806895 | Treatment of rheumatoid arthritis in patients with concomitant chronic hepatitis C infection |
| Q38705509 | Tumor Necrosis Factor Inhibits Spread of Hepatitis C Virus Among Liver Cells, Independent From Interferons |
| Q41260795 | Tumor necrosis factor-α antagonist therapy for concomitant rheumatoid arthritis and hepatitis C virus infection: a case series study |
| Q26829390 | Tumor necrosis factor-α inhibitors and chronic hepatitis C: a comprehensive literature review |
| Q44464843 | Use of biological disease-modifying anti-rheumatic drugs in patients with concurrent rheumatic disease and hepatitis B. |
| Q37765836 | Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action |
| Q82719630 | [Infectious complications of biologic therapy in patients with rheumatoid arthritis] |
Search more.